Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | CTSC | P53634 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10576425 | 1.00 | F2 (0.44) | F2GRM2GRM3CYP1A2ALOX15 | |
| SCHEMBL7864750 | 1.00 | F2 (0.44) | F2GRM2GRM3CYP1A2ALOX15 | |
| SCHEMBL10219312 | 0.91 | CHRNA1 (0.40) | F2GRM2GRM3CYP1A2ALOX15 | |
| SCHEMBL12166535 | 0.87 | F2 (0.47) | F2GRM2GRM3CYP1A2ALOX15 | |
| SCHEMBL10995985 | 0.85 | CCR2 (0.41) | F2GRM2GRM3CYP1A2ALOX15 | |
| SCHEMBL10987696 | 0.84 | MEN1 (0.46) | GRIN2BOPRM1OPRL1GAA | |
| SCHEMBL10995445 | 0.84 | CCR2 (0.45) | GRM2GRM3CYP1A2ALOX15GRIN2B | |
| SCHEMBL10991010 | 0.84 | SLC6A4 (0.43) | GRM2GRM3CYP1A2ALOX15 | |
| SCHEMBL10994563 | 0.82 | P2RY14 (0.42) | GRM2GRM3CYP1A2ALOX15OPRM1 | |
| SCHEMBL10996128 | 0.80 | GRM2 (0.38) | F2GRM2GRM3CYP1A2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4851514-A | ANGIOTENSIN CONVERTING ENZYME INHIBITOR, REACTING CERIUM TRICHLORIDE WITH PHENYLLITHIUM TO PRODUCE TRIPHENYL CERIUM | E. R. SQUIBB & SONS, INC. (US) | 1989-07-25 | — | — | US | claimed |
| US-4734508-A | GRIGNARD REACTION WITH TRIPHENYLCERIUM | E. R. SQUIBB & SONS, INC. (US) | 1988-03-29 | — | — | US | claimed |
| US-20100087382-A1 | Inhibitors of Hepatitis C NS3 Protease | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-08 | — | — | US | disclosed |
| US-4851514-A | ANGIOTENSIN CONVERTING ENZYME INHIBITOR, REACTING CERIUM TRICHLORIDE WITH PHENYLLITHIUM TO PRODUCE TRIPHENYL CERIUM | E. R. SQUIBB & SONS, INC. (US) | 1989-07-25 | — | — | US | disclosed |
| US-4734508-A | GRIGNARD REACTION WITH TRIPHENYLCERIUM | E. R. SQUIBB & SONS, INC. (US) | 1988-03-29 | — | — | US | disclosed |
| US-4499287-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1985-02-12 | — | — | US | disclosed |
| US-4456761-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1984-06-26 | — | — | US | disclosed |
| US-4356182-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1982-10-26 | — | — | US | disclosed |
| US-4291040-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1981-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087382-A1 | Inhibitors of Hepatitis C NS3 Protease | RNASE1, GTF3C3, CTRL | F2 737/4885GRM2 4839/4885GRM3 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.